381 related articles for article (PubMed ID: 27997533)
21. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel Somatic
Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
[TBL] [Abstract][Full Text] [Related]
23. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
24. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.
Dobilas A; Chen Y; Brueffer C; Leandersson P; Saal LH; Borgfeldt C
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):763-770. PubMed ID: 38035709
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer.
Zhu JW; Wong F; Szymiczek A; Ene GEV; Zhang S; May T; Narod SA; Kotsopoulos J; Akbari MR
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762691
[TBL] [Abstract][Full Text] [Related]
27. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
Tuna M; Ju Z; Yoshihara K; Amos CI; Tanyi JL; Mills GB
Br J Cancer; 2020 Feb; 122(3):405-412. PubMed ID: 31780779
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
[No Abstract] [Full Text] [Related]
30. Monitoring gastric cancer progression with circulating tumour DNA.
Hamakawa T; Kukita Y; Kurokawa Y; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Taniguchi K; Takiguchi S; Mori M; Doki Y; Kato K
Br J Cancer; 2015 Jan; 112(2):352-6. PubMed ID: 25490524
[TBL] [Abstract][Full Text] [Related]
31. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
32. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
Han MR; Lee SH; Park JY; Hong H; Ho JY; Hur SY; Choi YJ
Cancer Res Treat; 2020 Jul; 52(3):779-788. PubMed ID: 32106643
[TBL] [Abstract][Full Text] [Related]
33. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
De Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V; Piscuoglio S; Oliveira M; Smolders Y; Patel P; Norton L; Tabernero J; Berger MF; Seoane J; Reis-Filho JS
Ann Oncol; 2014 Sep; 25(9):1729-1735. PubMed ID: 25009010
[TBL] [Abstract][Full Text] [Related]
34. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
[TBL] [Abstract][Full Text] [Related]
35. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
[TBL] [Abstract][Full Text] [Related]
37. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
38. Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
Goranova T; Ennis D; Piskorz AM; Macintyre G; Lewsley LA; Stobo J; Wilson C; Kay D; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Freeman S; Moore L; Jimenez-Linan M; Paul J; Brenton JD; McNeish IA
Br J Cancer; 2017 May; 116(10):1294-1301. PubMed ID: 28359078
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
40. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]